Effects of social determinants of health on mortality and incident liver‐related events and cardiovascular disease in steatotic liver disease
Alimentary Pharmacology & Therapeutics · 2023-09 · 58 (5) · 537-545
DOI: 10.1111/apt.17631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 03.07.2023. Verfasst von Vincent L Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fatty Liver. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Division of Diabetes, Endocrinology, and Metabolic Diseases.
Abstract (Originalsprache)
Background
Social determinants of health (SDOH) are becoming increasingly recognised as mediators of human health. In the setting of metabolic dysfunction‐associated steatotic liver disease (MASLD), most of the literature on SDOH relates to individual‐level risk factors. However, there are very limited data on neighbourhood‐level SDOH in MASLD.
Aim
To assess whether SDOH impact fibrosis progression in patients who already have MASLD.
Methods
This was a retrospective cohort study of patients with MASLD seen at Michigan Medicine. The primary predictors were two neighbourhood‐level SDOH, ‘disadvantage’ and ‘affluence’. The primary outcomes were mortality, incident liver‐related events (LREs) and incident cardiovascular disease (CVD). We modelled these outcomes using Kaplan–Meier statistics for mortality and competing risk analyses for LREs and CVD, using a 1‐year landmark.
Results
We included 15,904 patients with MASLD with median follow‐up of 63 months. Higher affluence was associated with lower risk of overall mortality (hazard ratio 0.49 [0.37–0.66], p < 0.0001 for higher vs. lower quartile), LREs (subhazard ratio 0.60 [0.39–0.91], p = 0.02) and CVD (subhazard ratio 0.71 [0.57–0.88], p = 0.0018). Disadvantage was associated with higher mortality (hazard ratio 2.08 [95% confidence interval 1.54–2.81], p < 0.0001 for the highest vs. lowest quartile) and incident CVD (subhazard ratio 1.36 [95% confidence interval 1.10–1.68], p < 0.0001). These findings were robust across several sensitivity analyses.
Discussion
Neighbourhood‐level SDOH are associated with mortality, incidence of LREs and incident CVD in patients with steatotic liver disease. Interventions aimed at disadvantaged neighbourhoods may improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Vincent L Chen, Michael W Song
Förderung
- NIDDK NIH HHS
- Division of Diabetes, Endocrinology, and Metabolic Diseases
Zitieren
APA
Chen, V. L., Song, M. W., Suresh, D., Wadhwani, S. I., & Perumalswami, P. (2023). Effects of social determinants of health on mortality and incident liver‐related events and cardiovascular disease in steatotic liver disease. Alimentary Pharmacology & Therapeutics, 58(5), 537-545. https://doi.org/10.1111/apt.17631
Vancouver
Chen VL, Song MW, Suresh D, Wadhwani SI, Perumalswami P. Effects of social determinants of health on mortality and incident liver‐related events and cardiovascular disease in steatotic liver disease. Alimentary Pharmacology & Therapeutics. 2023;58(5):537-545. doi:10.1111/apt.17631
BibTeX
@article{Chen2023,
author = {Chen, Vincent L and Song, Michael W and Suresh, Deepika and Wadhwani, Sharad I and Perumalswami, Ponni},
title = {Effects of social determinants of health on mortality and incident liver‐related events and cardiovascular disease in steatotic liver disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {58},
number = {5},
pages = {537--545},
doi = {10.1111/apt.17631}
}
EUVIMED